SHR-1812

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameSHR-1812

Drug Alias NameSHR-1812

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3CD276 antigen inhibitors

TargetsT cell surface glycoprotein CD3CD276 antigen

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesJiangsu Hengrui Medicine Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJiangsu Hengrui Medicine Co Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A